Patents by Inventor Paula Hochman
Paula Hochman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160250340Abstract: An interferon beta polypeptide comprising interferon-beta 1a coupled to a polymer containing a polyalkylene glycol moiety wherein the interferon-beta-1a and the polyalkylene glycol moiety are arranged such that the interferon-beta-1a has an enhanced activity relative to another therapeutic form of interferon beta (interferon-beta-1b) and exhibits no decrease in activity as compared to non-conjugated interferon-beta-1a. The conjugates of the invention are usefully employed in therapeutic as well as non-therapeutic, e.g., diagnostic, applications.Type: ApplicationFiled: April 18, 2016Publication date: September 1, 2016Applicant: BIOGEN MA INC.Inventors: Blake PEPINSKY, Laura RUNKEL, Margot BRICKELMAIER, Adrian WHITTY, Paula HOCHMAN
-
Patent number: 9314534Abstract: An interferon beta polypeptide comprising interferon-beta 1a coupled to a polymer containing a polyalkylene glycol moiety wherein the interferon-beta-1a and the polyalkylene glycol moiety are arranged such that the interferon-beta-1a has an enhanced activity relative to another therapeutic form of interferon beta (interferon-beta-1b) and exhibits no decrease in activity as compared to non-conjugated interferon-beta-1a. The conjugates of the invention are usefully employed in therapeutic as well as non-therapeutic, e.g., diagnostic, applications.Type: GrantFiled: August 16, 2012Date of Patent: April 19, 2016Assignee: Biogen MA Inc.Inventors: Blake Pepinsky, Laura Runkel, Margot Brickelmaier, Adrian Whitty, Paula Hochman
-
Publication number: 20150011732Abstract: An interferon beta polypeptide comprising interferon-beta 1a coupled to a polymer containing a polyalkylene glycol moiety wherein the interferon-beta-1a and the polyalkylene glycol moiety are arranged such that the interferon-beta-1a has an enhanced activity relative to another therapeutic form of interferon beta (interferon-beta-1b) and exhibits no decrease in activity as compared to non-conjugated interferon-beta-1a. The conjugates of the invention are usefully employed in therapeutic as well as non-therapeutic, e.g., diagnostic, applications.Type: ApplicationFiled: August 16, 2012Publication date: January 8, 2015Inventors: Blake Pepinsky, Laura Runkel, Margot Brickelmaier, Adrian Whitty, Paula Hochman
-
Publication number: 20090286958Abstract: A fusion polypeptide is described having the amino acid sequence X-Y-Z, or portion thereof, comprising the amino acid sequence of a glycosylated interferon-beta (X); Y is an optional linker moiety; and Z is a polypeptide comprising at least a portion of a polypeptide other than glycosylated interferon-beta. It is preferred that X is human interferon-beta-1a. Mutants of interferon-beta-1a are also described.Type: ApplicationFiled: March 18, 2009Publication date: November 19, 2009Applicant: Biogen Idec MA Inc.Inventors: Adrian Whitty, Laura Runkel, Margot Brickelmaier, Paula Hochman
-
Patent number: 7527946Abstract: A fusion polypeptide is described having the amino acid sequence X-Y-Z, or portion thereof, comprising the amino acid sequence of a glycosylated interferon-beta (X); Y is an optional linker moiety; and Z is a polypeptide comprising at least a portion of a polypeptide other than glycosylated interferon-beta. It is preferred that X is human interferon-beta-1a. Mutants of interferon-beta-1a are also described.Type: GrantFiled: June 15, 2004Date of Patent: May 5, 2009Assignee: Biogen Idec MA Inc.,Inventors: Adrian Whitty, Laura Runkel, Margot Brickelmaier, Paula Hochman
-
Publication number: 20090104150Abstract: An interferon beta polypeptide comprising interferon-beta 1a coupled to a polymer containing a polyalkylene glycol moiety wherein the interferon-beta-1a and the polyalkylene glycol moiety are arranged such that the interferon-beta-1a has an enhanced activity relative to another therapeutic form of interferon beta (interferon-beta-1b) and exhibits no decrease in activity as compared to non-conjugated interferon-beta-1a. The conjugates of the invention are usefully employed in therapeutic as well as non-therapeutic, e.g., diagnostic, applications.Type: ApplicationFiled: March 20, 2008Publication date: April 23, 2009Inventors: Blake Pepinsky, Laura Runkel, Margot Brickelmaier, Adrian Whitty, Paula Hochman
-
Patent number: 7446173Abstract: An interferon beta polypeptide comprising interferon-beta 1a coupled to a polymer containing a polyalkylene glycol moiety wherein the interferon-beta-1a and the polyalkylene glycol moiety are arranged such that the interferon-beta-1a has an enhanced activity relative to another therapeutic form of interferon beta (interferon-beta-1b) and exhibits no decrease in activity as compared to non-conjugated interferon-beta-1a. The conjugates of the invention are usefully employed in therapeutic as well as non-therapeutic, e.g., diagnostic, applications.Type: GrantFiled: March 16, 2004Date of Patent: November 4, 2008Assignee: Biogen Idec MA Inc.Inventors: Blake Pepinsky, Laura Runkel, Margot Brickelmaier, Adrian Whitty, Paula Hochman
-
Publication number: 20070098688Abstract: An interferon beta polypeptide comprising interferon-beta 1a coupled to a polymer containing a polyalkylene glycol moiety wherein the interferon-beta-1a and the polyalkylene glycol moiety are arranged such that the interferon-beta-1a has an enhanced activity relative to another therapeutic form of interferon beta (interferon-beta-1b) and exhibits no decrease in activity as compared to non-conjugated interferon-beta-1a. The conjugates of the invention are usefully employed in therapeutic as well as non-therapeutic, e.g., diagnostic, applications.Type: ApplicationFiled: March 16, 2004Publication date: May 3, 2007Inventors: Blake Pepinsky, Laura Runkel, Margot Brickelmaier, Adrian Whitty, Paula Hochman
-
Patent number: 6962978Abstract: An interferon beta polypeptide comprising interferon-beta 1a coupled to a polymer containing a polyalkylene glycol moiety wherein the interferon-beta-1a and the polyalkylene glycol moiety are arranged such that the interferon-beta-1a has an enhanced activity relative to another therapeutic form of interferon beta (interferon-beta-1b) and exhibits no decrease in activity as compared to non-conjugated interferon-beta-1a. The conjugates of the invention are usefully employed in therapeutic as well as non-therapeutic, e.g., diagnostic, applications.Type: GrantFiled: April 11, 2001Date of Patent: November 8, 2005Assignee: Biogen, Inc.Inventors: Blake Pepinsky, Laura Runkel, Margot Brickelmaier, Adrian Whitty, Paula Hochman
-
Publication number: 20050214253Abstract: A fusion polypeptide is described having the amino acid sequence X-Y-Z, or portion thereof, comprising the amino acid sequence of a glycosylated interferon-beta (X); Y is an optional linker moiety; and Z is a polypeptide comprising at least a portion of a polypeptide other than glycosylated interferon-beta. It is preferred that X is human interferon-beta-1a. Mutants of interferon-beta-1a are also described.Type: ApplicationFiled: June 15, 2004Publication date: September 29, 2005Inventors: Adrian Whitty, Laura Runkel, Margot Brickelmaier, Paula Hochman
-
Publication number: 20050037003Abstract: This invention relates to compositions and methods comprising “lymphotoxin-? receptor blocking agents”, which block lymphotoxin-? receptor signalling. Lymphotoxin-? receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-? receptor extracellular domain that act as lymphotoxin-? receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-? receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-? receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-? receptor signalling is provided.Type: ApplicationFiled: February 15, 2002Publication date: February 17, 2005Inventors: Jeffrey Browning, Christopher Benjamin, Paula Hochman
-
Patent number: 6800735Abstract: A fusion polypeptide is described having the amino acid sequence X-Y-Z, or portion thereof, comprising the amino acid sequence of a glycosylated interferon-beta (X); Y is an optional linker moiety; and Z is a polypeptide comprising at least a portion of a polypeptide other than glycosylated interferon-beta. It is preferred that X is human interferon-beta-1a. Mutants of interferon-beta-1a are also described.Type: GrantFiled: April 11, 2001Date of Patent: October 5, 2004Assignee: Biogen, Inc.Inventors: Adrian Whitty, Laura Runkel, Margot Brickelmaier, Paula Hochman
-
Publication number: 20030021765Abstract: An interferon beta polypeptide comprising interferon-beta 1a coupled to a polymer containing a polyalkylene glycol moiety wherein the interferon-beta-1a and the polyalkylene glycol moiety are arranged such that the interferon-beta-1a has an enhanced activity relative to another therapeutic form of interferon beta (interferon-beta-1b) and exhibits no decrease in activity as compared to non-conjugated interferon-beta-1a. The conjugates of the invention are usefully employed in therapeutic as well as non-therapeutic, e.g., diagnostic, applications.Type: ApplicationFiled: April 11, 2001Publication date: January 30, 2003Inventors: Blake Pepinsky, Laura Runkel, Margot Brickelmaier, Adrian Whitty, Paula Hochman
-
Publication number: 20020155547Abstract: A fusion polypeptide is described having the amino acid sequence X—Y—Z, or portion thereof, comprising the amino acid sequence of a glycosylated interferon-beta (X); Y is an optional linker moiety; and Z is a polypeptide comprising at least a portion of a polypeptide other than glycosylated interferon-beta. It is preferred that X is human interferon-beta-1a. Mutants of interferon-beta-1a are also described.Type: ApplicationFiled: April 11, 2001Publication date: October 24, 2002Inventors: Adrian Whitty, Laura Runkel, Margot Brickelmaier, Paula Hochman
-
Publication number: 20020132317Abstract: The present invention provides novel isolated interferon-induced tetraspan (“IIT”) polynucleotides and polypeptides encoded by the IIT polynucleotides. Also provided are the antibodies that immunospecifically bind to an IIT polypeptide or any derivative, variant, mutant or fragment of the IIT polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the IIT polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, as well as to other uses.Type: ApplicationFiled: June 15, 2001Publication date: September 19, 2002Inventors: John A. Peyman, Antonio da Silva, Paula Hochman